Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
eIF4AIII CRISPR Activation Plasmid (m): sc-431393-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- eIF4AIII CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- eIF4AIII CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by eIF4AIII CRISPR Activation Plasmid (m) and eIF4AIII CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Eif4a3 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: eIF4AIII Antibody (B-2): sc-365549
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
eIF4AIII CRISPR Activation Plasmid (m) | sc-431393-ACT | 20 µg | $397.00 | |||
eIF4AIII CRISPR Activation Plasmid (m2) | sc-431393-ACT-2 | 20 µg | $397.00 |
Mouse Eif4a3 encodes eIF4AIII, a DEAD-box RNA helicase that functions as a core component of the exon junction complex and couples pre-mRNA splicing to downstream mRNA surveillance. eIF4AIII helps deposit and stabilize the exon junction complex on spliced transcripts, supporting nonsense-mediated mRNA decay, mRNA export, and translational control. Through these RNA processing pathways, Eif4a3 influences global gene expression programs important for cell-cycle progression, differentiation, and stress responses. Dysregulation of exon junction complex function and nonsense-mediated decay has been linked to neurodevelopmental and cancer-relevant transcriptome instability, making Eif4a3 a useful node for mechanistic studies of RNA quality control.
eIF4AIII CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Eif4a3 expression without altering the underlying DNA sequence.
eIF4AIII CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Eif4a3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Eif4a3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous eIF4AIII expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Eif4a3 locus and enabling the study of eIF4AIII-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of eIF4AIII pathway restoration in tumor cells with silenced or reduced Eif4a3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.